Consequently, the procedures for participation in the Extraordinary General Meeting indicated in this press release (proxy representation, written questions, composition of the Committee and broadcast details) supplement those set out in the notice (avis) published in the Bulletins des Annonces Legales Obligatoires, no. 146 dated
Due to the ongoing COVID-19 pandemic and in accordance with emergency measures imposed by the French government, the Board of Directors of the Company has decided that the Extraordinary General Meeting will be conducted behind closed doors at the Company's headquarters located at Parc Eurasante, 885 Avenue Eugene Avinee, Loos (59120),
Terms of proxy representation at the Extraordinary General Meeting
In accordance with the Decree, a shareholder who has chosen to be represented by a proxy of its choice must notify its appointment to
The form must include the first and last name and address of the representative, the words 'As a representative', and must be dated and signed. The voting instructions are indicated in the 'I vote by post' section of the voting card for the Extraordinary General Meeting. The proxy holder must attach a copy of his proof of identity and, where applicable, a power of attorney of the legal person he represents. In accordance with the Decree and in order to be taken into account, the electronic message must be received by BNP Securities Services no later than the fourth day preceding the date of the Extraordinary General Meeting, i.e.
In accordance with the provisions of the Decree, each shareholder or each holder who has already voted by post, given proxy to the chairman of the meeting, or given proxy to a third party may choose another means of participation in the Extraordinary General Meeting provided that the new instruction issued by this shareholder reaches the Company (i) according to the terms and deadlines specified in this press release regarding the proxies given to third parties, and (ii) according to the legal terms and deadlines as specified in the notice of the Extraordinary General Meeting available on the Company's website for votes by post or proxies to the chairman for the Extraordinary General Meeting. Their initial instructions will then be revoked.
Written questions at the Extraordinary General Meeting
The shareholders are invited to send their written questions to the Company at the latest until the end of the second business day preceding the date of the Extraordinary General Meeting, i.e.
Composition of the committee of the Extraordinary General Meeting
The Extraordinary General Meeting will be chaired by Mr.
Given the current pandemic and in accordance with the provisions of the Decree, the Company informs that it has appointed as observers (scrutateurs) of the Extraordinary General Meeting: Biotech Avenir and
Extraordinary General Meeting broadcast details
A live audio broadcast of the Extraordinary General Meeting will be available on the Company's website (https://ir.genfit.com) and a replay will be available at the Investors section of our website (https://ir.genfit.com) under the 'Events' section and on the 'Shareholders Meeting' page under 'Financials', as soon as possible at the end of the Extraordinary General Meeting and at the latest before the end of the fifth business day after the Extraordinary General Meeting.
ABOUT
FORWARD LOOKING STATEMENTS
This press release is not an advertisement and does not constitute a prospectus for the purpose of the Prospectus Regulation.
This press release contains certain forward-looking statements with respect to
The use of certain words, including 'consider', 'contemplate', 'think', 'aim', 'expect', 'understand', 'should', 'aspire', 'estimate', 'believe', 'wish', 'may', 'could', 'allow', 'seek', 'encourage' or 'have confidence' or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations and the Company's continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 'Main Risks and Uncertainties' of the Company's 2019 Universal Registration Document filed with the AMF on
Contact:
Tel: +1 (617) 714 5252
Email: investors@genfit.com
(C) 2021 Electronic News Publishing, source